Cytokines, molecular biological abnormalities, and acute myelogenous leukemia

Leukemia Research

Volumn 21, Issue 4, 1997, Pages 299-312

  Preisler, Harvey D ^a   Sucai, Bi ^a   Venugopal, Parameswaran ^a   Raza, Azra ^a  

^a RUSH CANCER INSTITUTE   (United States)

Author keywords

AML; Cytokines; Pre leukemia; Proliferation

Indexed keywords

CYTARABINE; CYTOKINE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 1BETA; INTERLEUKIN 3; LISOFYLLINE; PROTEIN P53; TUMOR NECROSIS FACTOR ALPHA;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CELL PROLIFERATION; CYTOKINE PRODUCTION; DRUG CYTOTOXICITY; GENE EXPRESSION; GENE MUTATION; HUMAN; LEUKEMIA CELL; LYMPHOCYTE CLONE; MYELODYSPLASTIC SYNDROME; ONCOGENE RAS; PRIORITY JOURNAL; RETINOBLASTOMA; TUMOR SUPPRESSOR GENE;

ANIMALS; CYTOKINES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; LEUKEMIA, MYELOCYTIC, ACUTE;

EID: 0343990790     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0145-2126(96)00097-5     Document Type: Article

References (121)

1. Griffin J. D. & Lowenberg B. Clonogenic cells in acute myeloblastic leukemia. Blood, 1986, 68, 1185.
2. Delwel R., Salem M., Pellens C., Dorssers L., Wagemaker G., Clark S. & Lowenberg B. Growth regulation of human acute myeloid leukemia: effects of five recombinant hematopoietic factors in a serum-free culture system. Blood, 1988, 72, 1944.
3. Lapidot T., Sirard C., Vormoor J., Murdoch B., Hoang T., Caceres-Cortes J., Minden M., Paterson E., Caligiurl M. A. & Dick J. A cell initiating human acute myeloid leukaemia after transplantation into SCID mice. Nature, 1994, 367, 645.
4. Moore M. A. S., Spitzer G. & Williams N. Agar culture studies in 127 cases of untreated acute leukemia: the prognostic value of reclassification of leukemia according to in vitro growth characteristics. Blood, 1974, 44, 1.
5. Spitzer G., Dicke K. A. & Gehan A. A simplified in vitro classification for prognosis in adult acute leukemia: the application of in vitro results in remission-predictive models. Blood, 1976, 48, 795.
6. Bradbury D., Zhu Y. M. & Russell N. Regulation of Bcl2 expression and apoptosis in acute myelogenous leukemia cells by granulocyte-macrophage colony stimulating factor. Leukemia, 1994, 8, 786.
7. Cachia P. G., Taylor C., Thompson P. W., Tennant G., Pettersson T., Whittaker J. A., Burnett A. K., Jacobs A. & Padua R. A. Non-dysplastic myelodysplasia? Leukemia, 1994, 8, 677.
8. Beran M., Reizenstein P. & Uden A. M. Response to treatment in acute nonlymphatic leukaemia: prognostic value of colony-forming and colony-stimulating capacities of bone marrow and blood cells compared to other parameters. British Journal of Haematology, 1980, 44, 39.
9. Hunter A. E., Rogers S. Y., Roberts A. G., Barrett J. & Russell N. Autonomous growth of blast cells is associated with reduced survival in acute myeloblastic leukemia. Blood, 1993, 82, 899.
10. Lowenberg B., van Putten W. L. J., Touw I. P., Delwel R. & Santini V. Autonomous proliferation of leukemic cells in vitro as a determinant of prognosis in adult acute myeloid leukemia. New England Journal of Medicine, 1993, 328, 614.
11. Preisler H. D., Banavali S. D., Yin M., Venugopal P., Li Y. Q., Gaskin F. & Raza A. Parallel studies of clonogenic leukaemia cells and the leukaemia cell population as a whole in acute myelogenous leukemia. European Journal of Cancer, 1994, 30, 1511.
12. Preisler H. D., Raza A., Larson R., Goldberg J., Tricot G., Carey M. & Kukla C. Some reasons for the lack of progress in the treatment of acute myelogenous leukemia. Leukemia Research, 1991, 15, 773.
13. Preisler H. D. & Venugopal P. Regrowth resistance in leukemia and lymphoma: the need for a new system to classify treatment failure and for new approaches to treatment. Leukemia Research, 1994, 18, 149.
14. Raza A., Preisler H. D., Day R., Yasin Z., White L. M., Lykins J., Barcos M., Bennett J., Browman G., Goldberg J., Grunwald H., Larson R. & Vogler R. Direct relationship between remission duration in acute myeloid leukemia and cell cycle kinetics. A leukemia intergroup study. Blood, 1990, 76, 2191.
15. Preisler H. D., Raza A., Hegde U., Handa H. & Braun D. Regrowth resistance as a mechanism for comprehensive growth resistance and fms expression and treatment outcome in acute myelogenous leukemia. Advances in Blood Disorders, submitted.
16. Cozzolino F., Rubartelli A., Aldinucci D., Sitia R., Torcia M., Shaw A. & DiGuglielmo R. Interleukin 1 as an autocrine growth factor for acute myeloid leukemia cells. Proceedings of the National Academy of Sciences, 1989, 86, 2369.
17. Bradbury D., Rogers S., Kozlowski R., Bowen G., Reilly I. A. G. & Russell N. H. Interleukin-1 is one factor which regulates autocrine production of GM-CSF by the blast cells of acute myeloblastic leukaemia. British Journal of Hematology, 1990, 76, 488.
18. Rodriguez-Cimadevill J. C., Beauchemin V., Villeneuve L., Letendre F., Shaw A. & Hoang T. Coordinate secretion of interleukin-1β and granulocyte-macrophage colony-stimulating factor by the blast cells of acute myeloblastic leukemia: Role of interleukin-1 as an endogenous inducer. Blood, 1990, 76, 1481.
19. Oster W., Cicco N. A., Klein H., Hirano T., Kishimoto T., Lindmann A., Mertelsmann R. H. & Herrmann F. Participation of the cytokines interleukin 6, tumor necrosis factor-alpha, and interleukin 1-beta secreted by acute myelogenous leukemia blasts in autocrine and paracrine leukemia growth control. Journal of Clinical Investigation, 1989, 84, 451.
20. Bradbury D., Bowen G., Kozlowski R., Reilly I. & Russell N. Endogenous interleukin-1 can regulate the autonomous growth of the blast cells of acute myeloblastic leukemia by inducing autocrine secretion of GM-CSF. Leukemia, 1990, 4, 44.
21. Delwel R., van Buitenen C., Salem M., Bot F., Gillis S., Kaushansky K., Altrock B. & Lowenberg B. Interleukin-1 stimulates proliferation of acute myeloblastic leukemia cells by induction of granulocyte-macrophage colony-stimulating factor release. Blood, 1989, 74, 586.
22. Russell N. H. Autocrine growth factors and leukemic haemopoiesis. Blood Review, 1992, 6, 149.
23. Elbaz O., Budel L. M., Hoogerbrugge H., Touw I. P., Delwel R., Mahmoud L. A. & Lowenberg B. Tumor necrosis factor regulates the expression of granulocyte-macrophage colony-stimulating factor and interleukin-3 receptors on human acute myeloid leukemia cells. Blood, 1991, 77, 989.
24. Hoang T., Haman A., Goncalvers O., Wong G. G. & Clark S. C. Interleukin-6 enhances growth factor-dependent proliferation of the blast cells of acute myeloblastic leukemia. Blood, 1988, 72, 823.
25. Beauchemin V., Villeneuve L., Rodriguez-Cimadevilla J. C., Rajotte D., Kenney J. S., Clark S. C. & Hoang T. Interleukin-6 production by the blast cells of acute myeloblastic leukemia: regulation by endogenous interleukin-1 and biological implications. Journal of Cell Physiology, 1991, 148, 353.
26. Birg F., Rosnet O., Carbuccia N. & Birnbaum D. The expression of FMS, KIT and FLT3 in hematopoietic malignancies. Leukemia & Lymphoma, 1994, 13, 223.
27. Broudy V. C., Smith F. O., Lin N., Zsebo K. M., Egrie J. & Bernstein I. D. Blasts from patients with acute myelogenous leukemia express functional receptors for stem cell factor. Blood, 1992, 80, 60.
28. Goselink H. M., Williams D. E., Fibbe W. E., Wessls H. W., Beverstock G. C., Willemze R. & Falkenburg J. H. F. Effect of mast cell growth factor (c-kit ligand) on clonogenic leukemic precursor cells. Blood, 1992, 80, 750.
29. Budel L. M., Delwel R., v Buitenen C., Hoogerbrugge H. & Lowenberg B. Effects of mast cell growth factor on acute myeloid leukemia cells in vitro: effects of combinations with other cytokines. Leukemia, 1993, 7, 426.
30. Quentmeier D. H. & Drexler H. G. Effects of FLT3 ligand on human leukemia cells. II. Agonistic and antagonistic effects of other cytokines. Leukemia, 1996, 10, 271.
31. Keller J. R., Ortiz M. & Ruscetti F. W. Steel Factor (c-kit ligand) promotes the survival of hematopoietic stem/ progenitor cells in the absence of cell division. Blood, 1995, 86, 1757.
32. Shah A. J., Smogorzewska E. M., Hannum C. & Crooks G. Flt3 Ligand induces proliferation of quiescent human bone marrow CD34+CD38-cells and maintains progenitor cells in vitro. Blood, 1996, 87, 3563.
33. Bruserud O., Nesthus I., Buhring H. J. & Pawelec G. Cytokine modulation of interleukin 1 and tumor necrosis factor-α secretion from acute myelogenous leukemia blast cells in vitro. Leukemia Research, 1995, 19, 15.
34. Delwel R., van Byutebeb C., Salem M., Oosterom R., Touw I. & Lowenberg B. Hemopoietin-1 activity of interleukin-1 (IL-1) on acute myeloid leukemia colony-forming cells (AML-CFU) in vitro: IL-1 induces production of tumor necrosis factor-α which synergizes with IL-3 or granulocyte-macrophage colony-stimulating factor. Leukemia, 1990, 4, 557.
35. Munker R., Gasson J., Ogawa M. & Koeffler H. P. Recombinant human TNF induces production of granulocyte-monocyte colony-stimulating factor. Nature, 1986, 323, 79.
36. Zucali J. R., Broxmeyer H. E., Gross M. A. & Dinarello C. A. Recombinant human tumor necrosis α and β stimulate fibroblasts to produce hemopoietic growth factors in vitro. Journal of Immunology, 1988, 140, 840.
37. Caldwell J. & Emerson S. G. Interleukin-1α upregulates tumor necrosis factor receptors expressed by a human bone marrow stromal cell strain: Implications for cytokine redundancy and synergy. Blood, 1995, 86, 3364.
38. Nawroth P. P. Tumor necrosis factor/cachectin increases with endothelial cell receptors to release interleukin 1. Journal of Experimental Medicine, 1986, 163, 1363.
39. Griffin J. D., Rambladi A., Vellenga E., Young D. C., Ostapovicz D. & Cannistra S. A. Secretion of interleukin-1 by acute myeloblastic leukemia cells in vitro induces endothelial cells to secrete colony stimulation factors. Blood, 1987, 70, 1218.
40. Salem M., Delwel R., Touw I., Mahmoud L. A., Elbasousy E. M. & Lowenberg B. Modulation of colony stimulating factor (CSF) dependent growth of acute myeloid leukemia by tumor necrosis factor. Leukemia. 1990, 4, 37.
41. Elbaz O., Budel L. M., Hoogerbrugge H., Touw I. P., Delwel R., Mahmoud L. A. & Lowenberg B. Tumor necrosis factor down regulates granulocyte-colony stimulating factor receptor expression on human acute myeloid leukemia cells and granulocytes. Journal of Clinical Investigation, 1991, 87, 838.
42. Salem M., Delwel R., Touw I., Mahmoud L. A. Elbasousy E. M. & Lowenberg B. Modulation of colony stimulating factor (CSF) dependent growth of acute myeloid leukemia by tumor necrosis factor. Leukemia, 1990, 4, 37.
43. van der Schoot C., Jansen P., Poorter M., Wester M., von dem Borne A., Aarden L. & van Oers R. Interleukin-6 and interleukin-1 production in acute leukemia with monocytoid differentiation. Blood, 1989, 74, 2081.
44. Dinarello C. A. Biologic basis for interleukin-1 in disease. Blood, 1996, 87, 2095.
45. Rambaldi A., Torcia M., Bettoni S., Vannier E., Barbui T., Shaw A., Dinarello C. & Cozzolino. Modulation of cell proliferation and cytokine production in acute myeloblastic leukemia by interleukin-1 receptor antagonist and lack of its expression by leukemic cells. Blood, 1991, 78, 3248.
46. Wetzler M., Kurzrock R., Estrove Z., Estey & Talpaz M. Cytokine expression in adherent layer from patients with myelodysplastic syndrome and acute myeloid leukemia. Leukemia Research, 1995, 19, 23.
47. Preisler H. D., Raza A., Kukla C., Larson R., Goldberg J. & Browman G. IL1β expression and treatment outcome in acute myelogenous leukemia (AML). Blood, 1991, 78, 849.
48. Kornblau S. M., Xu H.-J., Zhang W., Hu S.-X., Beran M., Smith T. L., Hester J., Estey E., Benedict W. F. & Deisseroth A. B. Levels of retinoblastoma protein expression in newly diagnosed acute myelogenous leukemia. Blood, 1994, 84, 256.
49. Ahuja H. G., Jat P. S., Foti A., Bar-Eli M. & Cline M. J. Abnormalities of the retinoblastoma gene in the pathogenesis of acute leukemia. Blood, 1991, 78, 3259.
50. Imamura J., Miyoshi I. & Koeffler H. P. p53 in hematologic malignancies. Blood, 1994, 84, 2412.
51. Bos J. L., Vries M. V., Alex J., van der E. B. A., Janssen J. W. G., Delwel R., Loenberg B. & Colly L. P. Mutations N-ras predominate in acute myeloid leukemia. Blood, 1987, 69, 1237.
52. Tobal K., Pagliuca A., Bhatt B., Bhatt B., Bailey N., Ayton D. M. & Mufti G. J. Mutation of the human FMS Gene (M-CSF Receptor) in myelodysplastic syndromes and acute myeloid leukemia. Leukemia, 1990, 4, 486.
53. Horton L. E., Qian Y. & Templeton D. J. G1 cyclins control the retinoblastoma gene product growth regulation activity via upstream mechanisms. Cell Growth Differentiation, 1995, 6, 395.
54. 1 arrest and apoptosis. Cancer Research, 1994, 54, 1169.
55. Hartwell L. & Kastan M. Cell cycle control and cancer. Science, 1994, 266, 1821.
56. Hirama T. & Koeffler H. P. Role of the cyclin-dependent kinase inhibitors in the development of cancer. Journal of the American Society of Hematologists, 1995, 86, 841.
57. Khosravi R. & Der C. The Ras signal transduction pathway. Cancer Metastasis Review, 1994, 13, 67.
58. Zhu Y.-M., Bradbury D. A., Keith F. J. & Russell N. Absence of retinoblastoma protein expression results in autocrine production of interleukin-6 and promotes the autonomous growth of acute myeloid leukemia blast cells. Leukemia, 1994, 8, 1982.
59. Kornblau S. M., Xu H.-J., del Giglio A., Hu S.-H., Zhang W., Calvert L., Beran M., Estey E., Andreeff M., Trujillo J., Cork M. A., Smith T. L., Benedict W. F. & Deisseroth A. B. Clinical implications of decreased retinoblastoma protein expression in acute myelogenous leukemia. Cancer Research, 1992, 12, 4587.
60. Zhu Y.-M., Bradbury D. & Russell N. Expression of different conformations of p53 in the blast cells of acute myeloblastic leukaemia is related to in vitro growth characteristics. British Journal of Cancer, 1993, 68, 851.
61. Zhang Wei, Hu G., Estey E., Hester J. & Deisseroth A. Altered conformation of the p53 protein in myeloid leukemia cells and mitogen-simulated normal blood cells. Oncogene, 1992, 7, 1645.
62. Zhou M., Ma L. & Findley H. W. Abnormalities of p53 tumor suppressor gene and IL6 expression in childhood acute lymphoblastic leukemia. Blood, 1993, 82 abst. 196, 52a.
63. Margulies L. & Sehgal P. Modulation of the human interleukin-6 promoter (IL-6) and transcription factor C/EBPβ (NF-IL-6) activity by p53 species. Journal of Biochemistry, 1993, 268, 15096.
64. Lyons J., Janssen J. W. G., Bartram C., Layton M. & Mufti G. Mutation of Ki-ras and N-ras oncogenes in myelodysplastic syndromes. Blood, 1988, 71, 1707.
65. Verhoef G., Schouwer P., Ceuppens J., VanDamme J., Goossens W. & Booggerts M. Measurement of serum cytokine levels in patients with myelodysplastic syndromes. Leukemia, 1992, 6, 1268.
66. Demetri G. D., Ernst T. J., Pratt Ii E. S., Zenzie B. W., Rheinwald J. G. & Griffin J. D. Expression of ras oncogenes in cultured human cells alters the transcriptional and posttranscriptional regulation of cytokine genes. Journal of Clinical Investigation, 1990, 86, 1261.
67. Lubbert M., Oster W., Knopf H.-P., McCormick F., Mertelslmann R. & Herrmann F. N-RAS gene activation in acute myeloid leukemia: association with expression of interleukin-6. Leukemia, 1993, 7, 1948.
68. Ridge S., Worwood M., Oscier D., Jacobs A. & Padua R. FMS mutations in myelodysplastic, leukemic, and normal subjects. Proceedings of the National Academy of Sciences, U.S.A., 1990, 86, 1377.
69. Baer M. R., Watt C. C. & Preisler H. D. Expression of the GM-CSF, M-CSF, and il-1 genes in acute myelogenous leukemia cells is induced by in vitro cell processing. Blood, 1988, 72, 109a, Abst. 346.
70. Preisler H. D., Raza A., Larson R., Goldberg J., Tricot G., Browman G. & Bennett J. The relationship of the in vivo cell cycle characteristics and treatment outcome in acute myelogenous leukemia to the expression of the fms, and myc proto-oncogenes. Leukemia & Lymphoma, 1994, 14, 273.
71. Yin M., Gao X. Z., Wang Z. & Preisler H. D. Studies of the proliferation and differentiation of immature myeloid cells in vitro: 4: preculture characteristics and the behavior of myeloid leukemia cells in vitro. Cell Biochemistry Function, 1991, 9, 39.
72. Raza A., Preisler H. D., Li Y. Q., Larson R., Goldberg J., Browman G., Bennett J., Grunwald H., Vogler R. & Kukla C. Biological characteristics of newly diagnosed poor prognosis acute myelogenous leukemia. American Journal of Hematology, 1993, 42, 359.
73. Coltman C. A. Jr, Dixon D. O. Second malignancies complicating Hodgkin's disease: Southwest Oncology Group 10-year follow-up. Cancer Treatment Review, 1992, 66, 1023.
74. Greene M. H., Young R. C. & Merrill J. M. et al. Evidence of a treatment dose response in acute nonlymphocytic leukemias which occur after therapy of non-Hodgkin's lymphoma. Cancer Research, 1983, 43, 1891.
75. Baker A., Cachia P., Ridge S., McGlynn H., Clarke R., Whittaker J., Jacobs A. & Padua R. A. FMS mutations in patients following cytotoxic therapy for lymphoma. Leukemia Research, 1995, 19, 309.
76. Carter G., Hughes D. C., Clark R. E., McCormick F., Jacobs A., Whittaker J. A. & Padua R. A. RAS mutations in patients following cytotoxic therapy for lymphoma. Oncogene, 1990, 5, 411.
77. Carter G., Ridge S. & Padua R. A. Genetic lesions in preleukemia. Critical Reviews in Oncology, 1992, 3, 333.
78. Cachia P., Culligan D., Clark R., Whittacker J., Jacobs A. & Padua R. Clonal haemopoiesis following cytoxic therapy for lymphoma. Leukemia, 1993, 7, 795.
79. Preisler H. D. The effects of TNFα on the proliferation of myelodysplastic cells in vitro. Blood, submitted.
80. Backx B., Breeders L., Bot F. & Löwenberg B. Positive and negative effects of tumor necrosis factor on colony growth from highly purified normal marrow progenitors. Leukemia, 1991, 5, 66.
81. Raza A., Gezer S., Mundle S., Gao X. Z., Alvi S., Borok R., Rifkin S., Iftikhar A., Shetty V., Parcharidou A., Loew J., Marcus B., Khan Z., Chancy C., Showel J., Gregory S. & Preisler H. D. Apoptosis in bone marrow biopsies involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood, 1995, 86, 268.
82. Preisler H. D. A hypothesis regarding the development of acute myeloid leukemia from preleukemic disorders: the role of proto-oncogenes. Cancer Genetics & Cytogenetics, 1988, 32, 133.
83. Pedersen-Bjergaard J., Pedersen M., Roulston D. & Philip P. Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukemia. Blood, 1995, 86, 3542.
84. Pedersen B. & Ellegaard J. A factor encoded by 7q31 suppresses expansion of the 7q-clone and delays cytogenetic progression. Cancer Genetics & Cytogenetics, 1994, 78, 181.
85. Kalra R., Dale D., Freedman M., Bonilla M., Weinblatt M., Ganser A., Bowman P., Abish S., Priest J., Oseas R., Olson K., Paderange D. & Shannon K. Monosomy 7 and activating RAS mutations accompany malignant transformation in patients with congenital neutropenia. Blood, 1995, 86, 4579.
86. Stephenson J., Lizhen H. & Mufti G. Possible co-existence of Ras activation and monosomy 7 in the leukaemic transformation of myelodysplastic syndromes. Leukemia Research, 1995, 19, 741.
87. LeBeau M., Epsinosa R., Neuman W., Stock W., Roulston D., Larson R., Keinanen M. & Westbrook C. Cytogenetic and molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases. Proceedings of the National Academy of Sciences, U.S.A., 1993, 90, 5484.
88. Willman C. L., Sever C. E., Pallavicine M. G., Harada H., Tanaka N., Slovak M. L., Yamamoto H., Harada K., Meeker T. C., List A. D. & Taniguchi T. Delition of IRF-1, mapping to chromosome 5q31.1, in human leukemia and preleukemic myelodysplasia. Science, 1993, 259, 968.
89. Preisler H. D., Paper in preparation.
90. Abdollahi A., Lord K. A., Hoffman-Liebermann B. & Lieberman D. A. Interferon regulatory factor 1 is a myeloid differentiation primary response gene induced by interleukin 6 and leukemia inhibitory factor: role in growth. Cell Growth Differentiation, 1991, 2, 401.
91. Tanaka N., Ishihara M. & Taniguchi T. Suppression of c-myc or fosβ-induced cell transformation by the transcription factor IRF-1. Cancer Letters, 1994, 83, 191.
92. Tanaka N., Ishihara M., Kitagawa M., Harada H., Kimura T., Matsuyama T., Lamphier M. S., Aizawa S., Mak T. W. & Tainiguchi T. Cellular commitment to oncogene-induced transformation or apoptosis is dependent on the transcription factor IRF-1. Cell, 1994, 77, 829.
93. Gopal V., Hulette B., Li Y. Q., Kuvelkar R., Raza A., Larson R., Goldberg J., Tricot G., Bennett J. & Preisler H. D. C-myc and C-myb expression in acute myelogenous leukemia. Leukemia Research, 1992, 16, 1003.
94. Parcharidou A., Saikia T., Kochupillai V., Shetty V., Cato K., Wright-Quinones V., Showel J., Larson R., Goldberg J., Gregory S., Preisler H. D. & Raza A. Higher apoptosis in newly diagnosed high risk myeloid leukemia (HR-AML) evolving from myelodysplasia. Proceedings of the American Association for Cancer Research., 1995, 36, 221, Abst. 1315.
95. Handa H., Hegde H. & Preisler H. D. Unpublished observations.
96. Raza A., Bokhri J., Yousuf N., Mehdi A., Mazewski Z., Kahn S., Baker V. & Lampkin B. Cell cycle kinetic; studies in human cancers: development of three DNA specific labels in three decades. Archives in Pathology and Laboratory Medicine, 1991, 115, 873.
97. Land H., Parada L. F. & Weinberg R. A. Tumorigenic conversion of primary embryo fibroblasts requires at least two cooperating oncogenes. Nature, 1983, 304, 596.
98. Estey E. H., Dixon D., Kantarjian H. M., Keating M. J. McCredie K., Bodey G. P., Kurzrock R., Talpaz M. Freireich E. J., Deisseroth A. B. & Gutterman J. U. Treatment of poor-prognosis, newly diagnosed acute myeloid leukemia with ara-C and recombinant human granulocyte-macrophage colony-stimulating factor Blood, 1990, 75, 1766.
99. Buchner T., Hiddemann W., Koenigsmann M., Zuhlsdoif M., Wormann B., Boeckmann A., Freire E. A., Innig G. Maschmeyer G., Ludwig W.-D., Sauerland M. C., Heinecke A. & Schulz G. Recombinant human granulocyte-macrophage colony-stimulating factor after chemotherapy in patients with acute myeloid leukemia at higher age or after relapse. Blood, 1991, 76, 1190.
100. Stone R. M., Berg D. T., George S. L., Dodge R. K., Paciucci P. A., Schulman P., Lee E. J., Moore J. O., Powell B. L. & Schiffer C. A. Granulocyte-macrophage colony - stimulating factor after initial chemotherapy for elderly patients with primary acute myelogenous leukemia. New England Journal of Medicine, 1995, 332, 1712.
101. Dombret H., Chastang C., Fenaux P., Reiffers J., Bordessoule D., Bouabdallab R., Mandelli F., Ferrant A., Auzanneau G., Tilly H., Yver A. & Degos L. A controlled study of recombinant human granulocyte colony-stimulating factor in elderly patients after treatment for acute myelogenous leukemia. New England Journal of Medicine, 1995, 332, 1671.
102. Rowe J. M., Andersen J. W., Mazza J. J., Bennett J. M., Paietta E., Hayes F. A., Oette D., Cassileth P. A., Stadtmauer E. A. & Wiernik P. H. A Randomized placebo-controlled phase III study of granulocyte-macrophage colony-stimulating factor in adult patients (>55 to 70 years of age) with acute myelogenous leukemia: a study of the Eastern Cooperative Oncology Group (E1490). Blood, 1995, 86, 457.
103. Clarke E., Rice G., Weeks R., Jenkins N., Nelson R., Bianco J. & Singer J. Lisofylline inhibits transforming growth factor β release and enhances trilineage hematopoietic recovery after 5-fluorouracil. Cancer Research, 1996, 56, 105.
104. Samie A., Alvi S., Mundle S., Shetty V., Gregory S., Loew J., Larson R., Goldberg J., Preisler H. D. & Raza A. Effects of recombinant human granulocyte-macrophage colony stimulating factor (RHGM-CSF) on apoptosis and cell cycle kinetics in newly diagnosed high risk patients with acute myeloid leukemia (HR-AML). Blood, 1994, 84, 586a, Abst. 2328.
105. Estey E., Thall P. F., Kantarjian H., O'Brien S., Koller C. A., Beran M., Gutterman J., Deisseroth A. & Keating M. Treatment of newly diagnosed acute myelogenous leukemia with granulocyte-macrophage colony-stimulating factor (GM-CSF) before and during continuous-infusion high-dose ara-C+daunorubicin: comparison to patients treated without GM-CSF. Blood, 1992, 79, 2246.
106. Archimbaud E., Fenaux P., Reiffers J., Cordonnier C., Leblond V., Travade P., Troussard X., Tilly H., Auzanneau G., Marie J. P., French M. & Berger E. Granulocyte-macrophage colony-stimulating factor in association to timed-sequential chemotherapy with mitoxantrone, etoposide, and cytarabine for refractory acute myelogenous leukemia. Leukemia, 1993, 7, 372.
107. Gandi V., Estey E., Du M., Nowak B., Keating M. J. & Plunkett W. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte colony stimulating factor during therapy of acute myelogenous leukemia. Clinical Cancer Research, 1995, 1, 169.
108. Koistinen P., Wang C., Curtis J. E. & McCulloch E. A. Granulocyte-macrophage colony-stimulating factor and interleukin-3 protect leukemic blast. Leukemia, 1991, 5, 789.
109. Gao X. Z., Yin M. Y. & Preisler H. D. The effects of cytosine arabinoside and GM-CSF on leukemic cells in vitro. Anticancer Research, 1989, 9, 1053.
110. Collins M. K. L., Marvel J., Malde P. & Lopez-Rivas A. Interleukin 3 protects murine bone marrow cells from apoptosis induced by DNA damaging agents. Journal of Experimental Medicine, 1992, 176, 1043.
111. Van Der Lely N., Witte T. D., Wessels J., Raymakers R., Muus P. & Preijers F. In vitro response of blasts to Il-3, GM-CSF is different for individual AML patients: factors that stimulate leukemic clonogenic cells also enhance Ara-C cytotoxicity. Annals of Hematology, 1994, 68, 225.
112. Yin M., Venugopal P., Banavali S. D., Gartside P. & Preisler H. D. Effects of an IL-1β receptor antagonist on acute myeloid leukemia cells. Leukemia, 1992, 6, 898.
113. Preisler H. D., Venugopal P., Banavali S. D., Finke D. & Bokhari S. A. J. Multiparameter assessment of the cell cycle affects of bioactive and cytotoxic agents. Cancer Research, 1992, 52, 1.
114. Estrov Z., Kurzrock R., Wetzler M., Kantarjian H., Blake M., Harris D. & Gutterman J. U. k, Talpaz M. Suppression of chronic myelogenous leukemia colony growth by interleukin-1 (IL-1) receptor antagonist and soluble Il-1 receptors; a novel application for inhibitors of IL-1 activity. Blood, 1991, 78, 1476.
115. Zhu Y.-M., Bradbury D. A. & Russell N. H. Wild-type p53 is required for apoptosis induced by growth factor deprivation in factor-dependent leukaemic cells. British Journal of Cancer, 1994, 69, 468.
116. Williams G. T., Smith C. A., Spooncer E., Dexter T. M. & Taylor D. R. Hemopoietic colony stimulating factors promote cell survival by suppressing apoptosis. Nature, 1990, 343, 76.
117. Essner R., Rhoades K., McBride W., Morton D. & Economou J. S. IL-4 down-regulates IL-1 and TNF gene expression in human monocytes. Journal of Immunology, 1989, 142, 3857.
118. Wagteveld A., Esselink M., Limburg P., Hallie M. R. & Veilenga E. The effects of IL-1β and IL-4 on the proliferation and endogenous secretion of growth factors by acute myeloblastic leukemic cells. Leukemia, 1992, 6, 1020.
119. Stošič -Grujičič S., Basara N., Milenkovic P. & Dinarello C. A. Modulation of acute myeloblastic leukemia (AML) cell proliferation and blast colony formation by antisense oligomer for IL-1 Beta converting enzyme (ICE) and IL-1 receptor antagonist (IL-1ra). Journal of Chemotherapy, 1994, 7, 67.
120. Lee J., Laydon J., McDonnell P., Gallagher T., Kumar S., Green D., McNulty D., Bluementhal M. J., Keys J. R., Landvatter S., Strickler J., McLaughlin M., Siemens I., Fisher S., Livi G. P., White J. R., Adams J. L. & Young P. A protein kinase involved in the regulation of inflammatory cytokine biosynthesis. Nature, 1994, 372, 739.
121. Preisler H. D., Raza A. & Larson R. Alteration of the proliferative rate of acute myelogenous leukemia cells in vivo in patients. Blood, 1992, 80, 2600.